CALR mutations in myeloproliferative neoplasms

Mutant CALR is a novel, specific molecular marker detected in majority of patients with myeloproliferative neoplasms who are negative for JAK2 and MPL mutations. Use of this marker in the clinic may improve diagnostic and therapeutic decision making in these patients, according to the late-breaking abstract results presented at the 55th Annual Meeting of American Society of Hematology (ASH) in New Orleans, USA (7-10 December, 2013). Read more here.